The effect of metformin on adipokines levels: A systematic review and meta-analysis of randomized-controlled trials
Authors' conclusion
In general, considering the role of adipokines on metabolic disease and even chronic disease, this drug can be used as a potentially useful drug, especially in obese people, to improve these factors.
Study context
- Population
- Controlled studies examining the impact of metformin on adipokines (leptin, adiponectin, resistin) in different populations; five databases searched49 studies
- Comparison
- Metformin vs control
- Outcome
- Adipokine levels (leptin, adiponectin, resistin)
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
Adipokine levels
Each group vs controlWMD (leptin), ng/ml (95% CI)P value
Metformin
−3.06(−3.81 to −2.30)
P < 0.001Each group vs controlWMD (resistin), µg/mL (95% CI)P value
Metformin
−1.27(−2.22 to −0.31)
P = 0.009Further pooled results
Subgroup: BMI >30 kg/m² vs BMI ≤ 30 kg/m²
- With BMI >30 kg/m², metformin caused a significant decrease in leptin and an increase in adiponectin
Subgroups: lower dose (≤1500 mg/day) and younger age (<30 years)
- Metformin caused a significant increase in adiponectin at lower doses (≤1500 mg/day) and in younger people (<30 years)
Original publication
The effect of metformin on adipokines levels: A systematic review and meta-analysis of randomized-controlled trials. Diabetes Res Clin Pract. Published 26 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →